Colin Broom
Chief Executive Officer chez Pulmotect, Inc.
Fortune : 1 944 $ au 31/07/2023
Profil
Colin Broom is currently the Chief Executive Officer & Director at Pulmotect, Inc. He is also a Member at The Royal College of Physicians and a Member at the Faculty of Pharmaceutical Medicine.
Previously, he served as the Chief Executive Officer at Nabriva Therapeutics GmbH from 2014 to 2017.
He was also an Independent Director at NPS Pharmaceuticals, Inc. from 2009 to 2015.
From 2004 to 2014, he was the Chief Scientific Officer & Vice President at Shire ViroPharma, Inc. Additionally, he served as the VP-European Clinical Development & Medical Affairs at Amgen, Inc. from 2000 to 2003.
He was the Senior Vice President-Global Clinical Development at Hoechst Marion Roussel, Inc. in 1999.
He started his career as a Vice President at The Gi Co., Inc. in 1987.
Dr. Broom holds an undergraduate degree from University College London and a doctorate from St. George's University of London.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NABRIVA THERAPEUTICS PLC
0,04% | 31/01/2023 | 1 369 ( 0,04% ) | 1 944 $ | 31/07/2023 |
Postes actifs de Colin Broom
| Sociétés | Poste | Début |
|---|---|---|
| The Royal College of Physicians | Corporate Officer/Principal | - |
Pulmotect, Inc.
 Pulmotect, Inc. BiotechnologyHealth Technology Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX. | Chief Executive Officer | 30/09/2019 |
| Faculty of Pharmaceutical Medicine | Corporate Officer/Principal | - |
Anciens postes connus de Colin Broom
| Sociétés | Poste | Fin |
|---|---|---|
| NABRIVA THERAPEUTICS PLC | Chief Executive Officer | 24/07/2018 |
Nabriva Therapeutics GmbH
 Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Chief Executive Officer | 23/06/2017 |
| NPS PHARMACEUTICALS, INC. | Director/Board Member | 01/01/2015 |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Chief Tech/Sci/R&D Officer | 01/01/2014 |
| AMGEN INC. | Corporate Officer/Principal | 01/01/2003 |
Formation de Colin Broom
| University College London | Undergraduate Degree |
| St. George's University of London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| NABRIVA THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 7 |
|---|---|
NPS Pharmaceuticals, Inc.
 NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ. | Health Technology |
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Health Technology |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Health Technology |
| Faculty of Pharmaceutical Medicine | |
| Hoechst Marion Roussel, Inc. | |
The Gi Co., Inc.
 The Gi Co., Inc. Pharmaceuticals: OtherHealth Technology The Gi Company Inc. develops drugs to treat gastrointestinal and related diseases. It offers intestinal trefoil factor for the treatment of oral mucositis. The company also has projects in enteritis, proctitis, inflammatory bowel disease, erosive gastro esophageal reflux disease, peptic ulcer disease and gastrointestinal motility disorders, as well as clinical programs in erosive gastritis, ulcerative colitis and corneal wound healing. The company was founded in 1998 and is headquartered in Framingham, MA. | Health Technology |
Pulmotect, Inc.
Pulmotect, Inc. BiotechnologyHealth Technology Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX. | Health Technology |
